Disclosure Status and Associated Factors Among Children on Antiretroviral Therapy in Ethiopia

Walelign Atomsa Tucho1, Aderajew Nigusse Tekelehaimanot2, Mahilet Berhanu Habte2

  • 1Department of Disease Prevention and Control, Bench Sheko Zone Health Office, Mizan-Aman, Southwest Ethiopia.

Insights

Disclosure of HIV status to children remains low in Ethiopia. Factors like caregiver education and discussion with health professionals can improve HIV status disclosure rates for children on antiretroviral therapy (ART).

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • The World Health Organization (WHO) recommends HIV status disclosure to children aged 6-12 years.
  • Disclosure rates are notably low in resource-limited settings, especially in Ethiopia.
  • This study addresses the low HIV status disclosure among children in southwest Ethiopia.

Purpose of the Study:

  • To determine the prevalence of HIV status disclosure among HIV-infected children in southwest Ethiopia.
  • To identify factors associated with HIV status disclosure in this population.

Main Methods:

  • A facility-based cross-sectional study was conducted with caregivers of HIV-positive children (aged 6-15) in southwest Ethiopia.
  • Data were collected via interviewer-administered questionnaires and checklists.
  • Multivariable logistic regression analysis was used to identify predictors of disclosure.

Main Results:

  • The prevalence of HIV-positive status disclosure was 45.6%.
  • Independent predictors of disclosure included caregiver secondary education, discussion with health professionals, child age 10-15 years, duration on ART >5 years, hospital treatment follow-up, and having a treatment support group.
  • Caregiver discussion with health professionals (AOR=9.56) and child age 10-15 years (AOR=3.64) were significant factors.

Conclusions:

  • HIV status disclosure to children in the study area is low.
  • Caregiver education, communication with healthcare providers, child's age, ART duration, treatment setting, and support groups are key factors enabling disclosure.
  • Targeted interventions are needed to improve HIV status disclosure rates among children living with HIV.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
50
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.9K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.3K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
42
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
435
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
512